Exclusive Summary

• With the originator's compound patent expiring globally around 2023-2024, Dapagliflozin is currently a blockbuster generic in its golden window for capturing first/early-to-market opportunities and national tenders in emerging markets.
• Boasting triple commercial indications across Type 2 Diabetes, Heart Failure, and Chronic Kidney Disease, it targets a massive global population of over 537 million diabetics and 64 million heart failure patients, driving explosive and sustainable market demand.
• As a flagship SGLT2 inhibitor, it is included in the WHO Model List of Essential Medicines (EML) and strictly recommended as first-line or prioritized foundational therapy by top international guidelines including ADA, ESC, and KDIGO.
• Supported by China's completely integrated API-to-formulation manufacturing ecosystem, we offer significantly lower costs to maximize distributor margins, along with comprehensive ready-to-file ICH-CTD dossiers to empower fast-track regulatory approval globally.